News & Events

ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

Andrew Garrett, EVP Scientific Operations said “With the recent FDA announcement of its Complex Innovative Designs Pilot Meeting Program, targeted at innovative trial designs to inform regulatory decision making, the door is very much open for adaptive and other types of innovative design. ADDPLAN® neo provides an integrated and increasingly flexible solution that truly supports this innovation agenda by providing a validated tool that helps convert theory to practice.”

About ICON plc
ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,675 employees.